Novartis' Cosentyx Goes Head-To-Head With Humira
Executive Summary
With the initiation of EXCEED and SURPASS, Novartis is aiming to challenge Humira’s status as the preferred first-line biologic for ankylosing spondylitis and psoriatic arthritis.
You may also be interested in...
Tremfya And Taltz Provide PsA Highlights At EULAR
The spotlight was on anti-interleukin drugs at the Madrid meeting last week, especially their role in advancing the treatment of psoriatic arthritis.
Lilly's Taltz Gets Closer To A Level Playing Field With Novartis' Cosentyx
Lilly reported positive results for Taltz in a second Phase III study in ankylosing spondylitis and plans to file for FDA approval this year, which would give the IL-17A inhibitor a label similar to its rival Cosentyx, for which Novartis is working hard to build, maintain and grow market share.
Novartis Allays Concerns Over Cosentyx Sales Miss
The Swiss major has calmed investor fears over the growth trajectory of Cosentyx, maintaining that its move into first-line therapy in ankylosing spondylitis and psoriatic arthritis, as well as psoriasis, will continue to drive sales.